R. Kristeleit, A. Lisyanskaya, A. Fedenko, M. Dvorkin, A. de Melo, Y. Shparyk, I. Rakhmatullina, I. Bondarenko, N. Colombo, V. Svintsitskiy, L. Biela, M. Nechaeva, F. Raspagliesi, G. Scambia, D. Cibula, R. poka, A. Oaknin, T. Safra, B. Maćkowiak-Matejczyk, L. Ma
{"title":"鲁卡帕尼与化疗在晚期复发卵巢癌和有害brca突变患者中的疗效和安全性:来自ariel4的随机3期研究","authors":"R. Kristeleit, A. Lisyanskaya, A. Fedenko, M. Dvorkin, A. de Melo, Y. Shparyk, I. Rakhmatullina, I. Bondarenko, N. Colombo, V. Svintsitskiy, L. Biela, M. Nechaeva, F. Raspagliesi, G. Scambia, D. Cibula, R. poka, A. Oaknin, T. Safra, B. Maćkowiak-Matejczyk, L. Ma","doi":"10.1136/ijgc-2021-igcs.9","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":19692,"journal":{"name":"Oral abstracts","volume":"6 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2021-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"O009/#786 Rucaparib vs chemotherapy in patients with advanced, relapsed ovarian cancer and a deleterious brca mutation: efficacy and safety from ariel4, a randomized phase 3 study\",\"authors\":\"R. Kristeleit, A. Lisyanskaya, A. Fedenko, M. Dvorkin, A. de Melo, Y. Shparyk, I. Rakhmatullina, I. Bondarenko, N. Colombo, V. Svintsitskiy, L. Biela, M. Nechaeva, F. Raspagliesi, G. Scambia, D. Cibula, R. poka, A. Oaknin, T. Safra, B. Maćkowiak-Matejczyk, L. Ma\",\"doi\":\"10.1136/ijgc-2021-igcs.9\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":19692,\"journal\":{\"name\":\"Oral abstracts\",\"volume\":\"6 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2021-11-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Oral abstracts\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1136/ijgc-2021-igcs.9\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Oral abstracts","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1136/ijgc-2021-igcs.9","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
O009/#786 Rucaparib vs chemotherapy in patients with advanced, relapsed ovarian cancer and a deleterious brca mutation: efficacy and safety from ariel4, a randomized phase 3 study